Pfizer: Pfizer's Nurtec approved in Korea, intensifying CGRP migraine treatment competition

The Korean approval of Pfizer's Nurtec, an oral calcitonin gene-related peptide (CGRP) targeting drug for both acute and preventive treatment, is expected to further intensify competition in the domestic migraine treatment market.According to the Ministry of Food and Drug Safety, Pfizer Korea's oral